4-Hydroxy MET (4-HO-MET) is a psychoactive tryptamine (NPS), a structural variant of the endogenous neurotransmitter serotonin. 4-Hydroxy MET has hallucinogenic effects, affecting mood, movement, and cognitive function.

4-hydroxy DiPT hydrochloride is an 5-HT2A agonist that induces the head-twitch response (HTR) in mice, indicating psychoactivity.

4-CAB hydrochloride is an analog of p-chloroamphetamine, a psychoactive compound which inhibits the reuptake of serotonin (IC50 = 330 nM) and dopamine (IC50 = 2.3 μM).

4-Bromo-2,5-DMMA (Compound 2) has affinity for 5-HT2 binding sites. 4-Bromo-2,5-DMMA has an ED50 of 0.82 mg/kg in the rat discrimination tests.

2-Methyl-N,N-dimethyltryptamine (2,N,N-TMT, compound 15) has binding affinity for serotonin (5-HT) receptor, with the pA2 of 6.04. 2-Methyl-N,N-dimethyltryptamine plays an important role in neurological disease research.

2C-TFM hydrochloride is a ,5-dimethoxyphenethylamines compound with a para-trifluoromethyl substitution. 2C-TFM hydrochloride is a potent agonist of the 5-HT receptor subtypes 5-HT2A and 5-HT2C.

2C-B-FLY hydrochloride is the dihydrodifuran analog of the Schedule I hallucinogen 4-bromo-2,5-dimethoxyphenethylamine (2C-B).

25T7-NBOMe hydrochloride is a derivative of 2C-T-7, characterized by the addition of a benzyl-methoxy (BOMe) group to the amine.

25P-NBOMe hydrochloride is structurally categorized as a phenethylamine. 25P-NBOMe hydrochloride binds 5-HT receptors 5-HT2A and 5-HT2C with similar affinities.

25N-NBOMe hydrochloride, a 2C-N derivative, is a 5-HT2A and 5-HT2C receptors agonist with Ki values of 0.144 nM and 1.06 nM, respectively. 25N-NBOMe hydrochloride has little to no efficacy at inducing release of preloaded neurotransmitter from recombinant dopamine, serotonin and norepinephrine transporters.

25I-NBMD hydrochloride is a derivative of the phenethylamine 2C-I that increases the affinity and activity at the 5-HT2A receptor.

25I-NBF hydrochloride is a highly potent partial agonist for the 5-HT2A receptors receptor with a Ki value of 0.26 nM and an EC50 value of 1.6 nM.

25H-NBOMe hydrochloride is an agonist for the rat and human serotonin 5-HT2A receptors with Ki values of 1.19 and 2.83 nM, respectively.

25C-NBOH hydrochloride is a derivative of 2C-C having an N-(2-hydroxybenzyl) addition at the amine and is a potent agonist of 5-HT receptors that shows selectivity for 5-HT2A over 5-HT2C (EC50s = ~ 0.40 and 15 nM, respectively).

25C-NBF hydrochloride is an agonist of 5-HT receptors that activates 5-HT2A and 5-HT2C similarly (EC50s = ~0.3 μM for each).

25B-NBOH hydrochloride is structurally categorized as a phenethylamine that displays high affinity for the 5-HT receptors 5-HT2A and 5-HT2C (pKis = 8.3 and 9.4, respectively).

25B-NBF hydrochloride is a highly potent agonist for the 5-HT2C receptor binds human 5-HT2A receptors and rat 5-HT2C receptors with pKi values of 8.57 and 7.73, respectively.

2,4-DMA hydrochloride is an amphetamine and is a serotonin 5-HT2 receptor agonist with an apparent PA2 value of 5.6.

(S)-Ramosetron ((S)-YM060 free base) is an orally active antagonist of the 5-hydroxytryptamine 5-HT3 receptor. (S)-Ramosetron is promising for research of diseases related to nausea and vomiting, irritable bowel syndrome (IBS).

(S)-PF-04995274 is a partial agonist of the 5-hydroxytryptamine receptor 4 (5-HT4R) and is an isomer of PF-04995274.

YDR1 is a potent, selective and orally bioavailable Cereblon-based PROTAC and a degrader of SMARCA2 with DC50 of 60 nM at 48 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer.

YD54 is a potent, selective and orally bioavailable PROTAC and a degrader of SMARCA2 with DC50 of 8.1 nM at 24 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer.

Y16526 is a potent inhibitor of CBP/p300 bromodomain , with the IC50 of 0.03 μM. Y16524 has the potential for the research of acute myeloid leukemia (AML).

Y16524 is a potent inhibitor of CBP/p300 bromodomain , with the IC50 of 0.01 μM. Y16524 has the potential for the research of acute myeloid leukemia (AML).

XY221 (Compound 16o) selectively inhibits BRD4 BD2, with an IC50 of 5.8 nM. XY221 demonstrates high pan-BD2 selectivity (667-fold over BRD4 BD1) and BRD4 BD2 domain selectivity (9−32-fold over BRD2/3/T BD2). XY221 induce Apoptosis in MV4-11 cells and shows anticancer activity .

TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with KDs of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC50 of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 and class I HDAC inhibitor CI994. TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine.

trans-BAY-850 is the trans isomer of BAY-850.

SMD-3236 is a SMARCA2-targeted PRAOTAC degrader designed based on SMARCA ligands and VHL-1 ligands, with long-lasting antitumor activity in vivo. SMARCA2 is a synthetic lethal target in SMARCA4-deficient cancer cells, and SMD-3236 has a 2000-fold selectivity for degradation of SMARCA2 over SMARCA4, with a DC50< 1 nM and a Dmax>95%. SMD-3236 can induce SMARCA2 loss in tumor tissues while retaining SMARCA4 protein, and inhibit tumor growth in the H838 smarca4-deficient human cancer xenograft model.

PBRM1/SMARCA2,4 binder-1 is a binder of PBRM1, SMARCA2, and SMARCA4 (IC50: 0.083, 0.153, and 0.046 μM, respectively).

JV8 is a BRD4 PROTAC degrader. JV8 promotes the ubiquitination and degradation of BRD4 and induces apoptosis. JV8 has antitumor activity in a mouse 4T1 orthotopic tumor model.